What Was Deconstruction? – The Chronicle of Higher Education

In 1990, at the Humanities Research Institute at University of California at Irvine, I found myself sitting next to Jacques Derrida at a lecture given by Ernesto Laclau. The topic was Antonio Gramsci. At the end of the talk, of which I understood frustratingly little, Derrida asked a question that took about 20 minutes to formulate. Laclaus response was of equal length. This mattered, because the event was the only one open to the public (it was to be followed by an invitation-only seminar). Graduate students and professors packed the lecture hall and, like Laclau himself, deferentially hung on Derridas every word. But they never had time to speak. The episode struck me as symbolic of the reverence deconstruction commanded at the height of its influence and also of the hierarchies, buoyed by awestruck puzzlement, upon which it rested.

At a private reception the next day, I approached Derrida to press him on his comments, for his intervention at Laclaus lecture had, as far as I could tell, nothing to do with Gramsci. As I cited studies and quoted passages to support my point, Derrida looked up at me with quizzical eyes and a faint, perhaps condescending, smile. I was aware that my questions violated academic politesse, since to press the philosopher on issues about which he seemed ill-informed was impertinent. The underlying joke (which I also got, although I pretended not to) meant knowing that what Gramsci actually wrote, or why, hardly mattered at least here.

Now, 30 years down the road, it is surprisingly hard to remember why Derridas deconstruction a theory of reading with the unlikely catchphrase the metaphysics of presence swept all before it in English departments of the American heartland, prompted Newsweek to warn of its dramatic and destructive power, and moved prominent scholars like Ruth Marcus to denounce its semi-intelligible attacks on reason and truth. For decades the movements adages appeared as one-liners at Modern Language Association cash bars: literary language undoes its own premises, philosophy is the self-subversion of hierarchical oppositions. After all the high-powered careers, the junkets to Bellagio, the National Endowment for the Humanities cash, the Paul de Man scandal, and the hagiographies, its revolution has begun to seem less a bone of contention than the professions longest-running one-line joke.

To this day, deconstruction remains a style of thought more complained about than understood, less outrageous than deliberately elusive. Until the very end, its high-profile proponents contemptuously elected not to define it, insisting instead on its undefinability, which naturally led the unpersuaded (summoning a favorite movement term) to judge deconstruction an escomatage (a dodge or conjuring trick). After the revolution had become rote, critics no longer forced to bite their tongues pointed to Derridas wordplay (aigle for Hegel for instance; or hantologie for ontology), and noted that punning is the lowest form of humor. Could it be, some of us in the discipline began to wonder, that Derrida was the Herbert Spencer of our era a towering edifice in his time and a vacant epigone of Heidegger outside it?

The power of Gregory Jones-Katzs extraordinarily well-researched Deconstruction: An American Institution (University of Chicago Press, 2021), apart from dodging the extremes of obeisance and dismissal, is not to have adopted deconstructions aversion toward situating the movement in its time and place. He capably walks his reader through the fine-grained details of seminal texts, but also wisely moves beyond them, perhaps implying that the schools interest for us today lies less in its stable of familiar themes than in its improbable success. What made deconstruction soar when its philosophical points of departure, the genealogy of its methods, the clash between French and American intellectual culture, and the incompatible positions of its principal spokespersons were so poorly understood? The legacy of deconstruction seems to present us with two alternatives: It is either a story of a radical turn toward a reason freed from binary oppositions (man/woman, truth/falsity), or it is a conversion story with indecipherability its sacred sine qua non.

Grard Rondeau, Redux

In tackling this dilemma, Jones-Katz gives us plausible scenarios but leaves important ones unmentioned. Told as a story of ideas, deconstruction began with two unrelated moves. First, Derrida seized upon Husserls emphasis on the materiality of language, but also on Husserls timidity in reducing the sign to a mere representation, thereby diminishing its ontological force (writing, for Derrida, has material autonomy). Second, Paul de Man redirected the formalists emphasis on literary figures like irony, metonymy, and allegory to what he (confusingly) called rhetoric, which meant not the art of persuasion but the genetic, impersonal principle that literary texts dwell in contradiction and are thus impervious to resolution.

Told as a story of institutions, deconstruction took shape as the gathering of strong personalities who had the ears of their deans, and who nurtured these seeds into a program, a curriculum, and finally, a crusade. The power center featured Derrida, de Man, Geoffrey Hartman, J. Hillis Miller, and later, Barbara Johnson, and moved back and forth between Yale and Johns Hopkins, Cornell and (later) UC-Irvine, and its members saw themselves as the rescuers of a beleaguered literary studies which at the end of the postwar boom in the 1960s and 1970s was being pressured to defend its relevance and define its purpose. The profession was producing more Ph.D.s than jobs, and legislators were beginning to question the cost of higher education. At the same time, students honed to a sharp point by the civil-rights and feminist movements, as well as by opposition to the Vietnam War, demanded more than the aesthetic contemplation of a canon sealed off from the contagion of everyday life.

From the start, though, the deconstructive revolution was as self-contradictory as the literary language it studied. Touted as the mission of leftist radicals by the media, it was really the creation of midcareer professors at East Coast universities. Inspired by the New Left, it took its leads not from the policy-oriented, anti-colonial wing but the one decried by Thomas Frank for its lifestyle rebellions, obsessions with the personal, and hostility to all authority. While Jones-Katz does not exactly say so, the stage was set for deconstruction also by the threat of American scientism. In fields like eco-criticism, animal studies, and posthumanism that both mimic and deflect the sciences, Derrida remains immensely influential. There he is called upon, among other things, to virally infect communication and short-circuit the nature of thought itself. The book establishes, at any rate, that deconstruction was less a French invasion (as the media would have you believe) than an American invention, beginning with the recruitment of Derrida, lured to the United States only after his influence was beginning to wane in Europe and after the French minister of education denied him a chair at the University of Paris Nanterre.

As deconstruction developed over the 1980s and 1990s, its politics became harder and harder to read. For one thing, it was the brainchild of wildly different kinds of scholars: a literary romanticist and Nietzschean (de Man), a phenomenological philosopher (Derrida), a sociohistorical critic with Auerbachian beginnings (Hartman), an influence theorist (Harold Bloom), a critic of authorial consciousness (Miller), and feminists with affiliations ranging from new historicism and Lacanian psychoanalysis to Marxism (Johnson, Margaret Homans, Mary Poovey, Gayatri Chakravorty Spivak, and others). Unfortunately, Jones-Katz has nothing to say about the incoherence of this ensemble. Still, the jumble is the first sign that deconstruction, influential and enduring though it might be, is not what it seems.

Jones-Katz rightly observes, for example, that deconstruction sought to make criticism relevant to social needs. But then what could be more embarrassing in an era of trickle-down economics than a theory whose authority depended on an Ivy League seal of approval? The unseemly deference paid by the underfunded academic second-string toward New Haven theories packaged for the provinces was only matched by the indignant, but always eager, coverage of deconstructive antics in the mainstream press, ever alert to the goings-on at institutions with the smell of money (the outrageous professional perks, the cushy gigs, the Guggenheim Fellowships, the NEH and Ford Foundation largess, the island homes off the coast of Maine).

Deconstructions renovation of the humanities seemed equally at odds with its unmistakably religious undertones. Michel Foucault had already pointed out that giving writing a primal status and claiming writing as absence (two of Derridas signature moves) simply repeated the transcendental terms of the religious principle. (This is one reason Derrida remains influential among theologians.) Others took up this charge, wondering what an obsessive textualism based on the invisibility of all intention was if not Gnosticism. On the surface, deconstruction posed as a densely semantic investigation conducted with ruthless precision. And yet, all the while, it seemed to be playing a double game, winking at its readers by counting on them to recognize its Jesuitical, rabbinical, or Sufistic relationship to the Book.

Nominally a redoubt for vanguard critics, deconstruction in some quarters had the feel of an antiquarian rerun, part of that Gallic preciosity that Harry Levin dubbed the Alexandrianism of our time a return, in other words, to the obscure and ornamental writing of the last centuries before the Christian era; or perhaps to the exegetes of second-century Alexandria, among them Philo, who set out to prove that contradiction was the normal mode of all expression, and who proposed to undo the rational forms of Greek thought.

Although few could hear the point during theory fever, some observed that deconstructions attack on logocentrism created problems for liberatory politics. Barbara Harlow (one of Derridas early translators) observed that Western philosophy had, in fact, always given tendentious priority to the written word, to scripture, and the law not speech as Derrida contended. And what are Platos dialogues if not dissimulated speech skillfully managed in Socratess favor within the controlled ironies of writing? The technology of print in imperial Europe was the very brag of its civilization. How to escape, then, deconstructions implicit premise that peripheral traditions of storytelling, song, and word-of-mouth (what Ishmael Reed, after Booker T. Washington, called the grapevine telegraph) are illusory or nave? Texts for many cultures are oral, bodily, tonal, and rhythmic. They depend on communal gathering in short, on a metaphysics of presence.

One wishes Deconstruction in America had involved itself more with these kinds of interrogations. Its pages are given over too often to replaying mini-tussles at Yale or rehearsing minor essays. But Jones-Katz expresses well its principals considerable talents. The loyalty of de Mans students suggests a teacher whose dedication was, as it should be, legendary. Despite deconstructions bad rap, his essays on aesthetics and literary language are remarkably lucid, unpretentious, and pedagogically precise. Derridas erudition and attention to out-of-the-way texts, similarly, showed a creative, antinomian mind, and his powers to fashion syntax into the lure of an ever-receding referent to create the illusion of substance while ambiguating all referentiality was perhaps the highest mark of his brilliance.

At the same time, we need more theory than Jones-Katz provides to unpack deconstruction as theory. Ostensibly, we are exploring the ontology of language, but as the methodological incompatibility of its ensemble of practitioners implies, its real cohesion is not epistemological but ethical. The term deconstruction referred not to a set of philosophical concepts but to a desire, which was also a prescription, that there be (as Miller put it) no center, no head referent, no innermost core. In a post-radical era busy turning radicals into professionals, deconstruction with a great deal of philosophical noise fell back on Americas familiar modernist response to the partisans of all causes: There are no answers, no origins, no past, no perpetrators.

The move was deliberate. As Jones-Katz tells the story, de Mans teaching and mentorship were programmatic. Even an ally like Hartman reflected after his death: In the space war of the theorists, he became the Yoda figure, recruiting acolytes sent out into the profession to replicate his teachings. As Bloom complained, You clone, my dear. I dislike what you do as a teacher, because your students are as alike as two peas in a pod. With its Continental armature, deconstruction had the upper hand. Its adversaries were typically cast as uncharitable or clueless journalists, old-time empiricists, stale New Critics, or the Old World professoriate, handily dislodged (Ren Wellek, in particular, was a fall guy of this type).

Studiously avoided by its defenders was any mention of deconstructions formidable rivals and challengers: the literary sociology of Raymond Williams and Pierre Bourdieu; the materialist feminisms of Sylvia Wynter, Nancy Fraser, and Gayle Rubin; the more trenchant and capacious literary essays by Theodor Adorno, Leo Lowenthal, and Ernst Bloch; and the analytic philosopher John R. Searle, who deconstructed deconstruction with its own tools in The New York Review of Books to devastating and comic effect. Had deconstruction been more often forced to face the likes of Adornos demolition of Heideggers jargon of authenticity, it might have seemed more vulnerable.

As a body of propositions, it was never hard to probe deconstructions weaknesses. Texts undid themselves, it claimed, whereas it was really the deconstructive text that did and intentionally so. Denouncing something so amorphous and pretentious as Western metaphysics partook of the same reductions the school wanted to expose in other paradigms. What could be more damning than pointing out that deconstruction, against its own tenets, opposed opposition? This ultimate performative contradiction lay in claiming that semantic plenitude resists interpretation in the very act of writing that stood as proof of an effort to persuade. What its critics overlooked is that deconstruction triumphed in part by giving its readers less to think about. Its weaknesses gave it strength because running and dodging was its professed mode, so that pointing out its contradictions was a little like getting in its groove.

In this way, its politics seemed perfect for an American setting of plausible deniability. Feminism can apply deconstruction to male metaphysics and gendered and sexed hierarchical oppositions without having to reckon with the fact that in deconstruction metaphysics means the illusory belief that signifiers have worldly referents and hierarchy the taking of a stand, any stand. For Derrida, taking a position is itself hierarchical. The grievances of women can be addressed in deconstruction only at the cost of effacing all contestation. Deconstructions doctrine of interpretive play turns meaning over to a joyous, Nietzschean affirmation, which boils down to the claim that, like the Reagan administrations perverse reading of the SALT II treaty, anything goes.

In the end, deconstruction seems most American in giving repressive tolerance philosophical dignity. In a country where one can speak against the national nightmare so long as one is not heard, the only mainstream dissidence that probes the angry pulse of Americas fascist heart is found in stand-up comedy or fiction, where irony offers the safety of escape. As in the Monty Python sketch, the diligent truth-tellers of the alternative press are just so many Ernest Scribblers. Deconstruction won credence for the left by enlisting the European philosophical right; and was widely welcomed by the liberal center of academe because in attacking oppressive credos it was undermining credibility itself.

Link:

What Was Deconstruction? - The Chronicle of Higher Education

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging – MIT Technology Review

The Saudi royal family has started a not-for-profit organization called the Hevolution Foundation that plans to spend up to $1 billion a year of its oil wealth supporting basic research on the biology of aging and finding ways to extend the number of years people live in good health, a concept known as health span.

The sum, if the Saudis can spend it, could make the Gulf state the largest single sponsor of researchers attempting to understand the underlying causes of agingand how it might be slowed down with drugs.

The foundation hasnt yet made a formal announcement, but the scope of its effort has been outlined at scientific meetings and is the subject of excited chatter among aging researchers, who hope it will underwrite large human studies of potential anti-aging drugs.

The fund is managed by Mehmood Khan, a former Mayo Clinic endocrinologist and the onetime chief scientist at PespsiCo, who was recruited to the CEO job in 2020. Our primary goal is to extend the period of healthy lifespan, Khan said in an interview. "There is not a bigger medical problem on the planet than this one.

MS TECH | GETTY

The idea, popular among some longevity scientists, is that if you can slow the body's aging process, you can delay the onset of multiple diseases and extend the healthy years people are able to enjoy as they grow older. Khan says the fund is going to give grants for basic scientific research on what causes aging, just as others have done, but it also plans to go a step further by supporting drug studies, including trials of treatments that are patent expired or never got commercialized.

We need to translate that biology to progress towards human clinical research. Ultimately, it wont make a difference until something appears in the market that actually benefits patients, Khan says.

Khan says the fund is authorized to spend up to $1 billion per year indefinitely, and will be able to take financial stakes in biotech companies. By comparison, the division of the US National Institute on Aging that supports basic research on the biology of aging spends about $325 million a year.

Hevolution hasnt announced what projects it will back, but people familiar with the group say it looked at funding a $100 million X Prize for age reversal technology and has reached a preliminary agreement to fund a test of the diabetes drug metformin in several thousand elderly people.

Read the original:
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging - MIT Technology Review

Never Take This After Age 50, Warn Pharmacists Eat This Not That – Eat This, Not That

Nutrition is crucial for healthy aging, but supplements are not as effective as food when it comes to getting the right amounts of vitamins and mineralsand some can actually be dangerous. "My motto is always 'food first,'" says Rachel Berman, R.D., Director of Nutrition for Calorie Count. "Foods found in nature are always more nutritious because our bodies are used to processing vitamins and minerals that come from natural sources." Here are five supplements you should never take after 50. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

A study from UC Davis showed that too much folic acid can aggravate complications related to vitamin B-12 deficiency, which could result in dangerous health conditions such as anemia and neurological damage. "There have been concerns that some people may be getting too much folic acid through a combination of sources, and we wanted to determine if there were reasons for those concerns," says Ralph Green, UC Davis professor of pathology and laboratory medicine. "Our results show that higher levels of folic acid could set in motion a metabolic imbalance that leads to more serious B-12 deficiency We do have to worry about folic-acid supplementation. The fact is that a lot of people are getting more of it than is good for them. If they happen to be B-12 deficient, more folic acid may actually harm them."

Hormone therapy such as HGH (human growth hormone) can be dangerous, experts warn. "In this entire field, I've only encountered one board-certified endocrinologist," says Thomas Perls, M.D., associate professor of medicine and geriatrics at Boston University School of Medicine. "It's outrageous that people think they can prescribe these toxic hormone soups There is no scientific proof of this. And studies show that increasing HGH levels with drugs predisposes people to heart disease, diabetes, and cancer."

6254a4d1642c605c54bf1cab17d50f1e

Anti-aging supplements have not been proven to work, experts warn, and most are not regulated by the FDA. "Many anti-aging doctors sell their own lines of nutraceuticals at very high prices," says Dr. Perls. "It's a profit margin that's better than what cocaine dealers get."

"We don't know if they could help, but they could be harmful," says Winifred K. Rossi, deputy director of the Division of Geriatrics and Gerontology at the National Institute on Aging.

Vitamin E is a common ingredient in brain health supplements, but too much can be dangerous.

"High doses of vitamin E supplements are associated with an increased risk of death," says dietitian Maxine Smith, RDN, LD, who recommends getting vitamin E from foods such as nuts, seeds, and dark green leafy vegetables.

Over-the-counter sexual enhancement products should be avoided, experts warn. "Products promising to enhance sexual performance have been promoted for over a century, dating back to the patent medicines of the 1800s; these products were characterized by wildly exaggerated claims and sold to the public by unscrupulous manufacturers, without evidence of safety or effectiveness," says W. Steven Pray, PhD, DPh. "Some manufacturers of impotence cures claim that their product is 'scientifically proven' to work. When a consumer sees the phrase 'clinical studies prove it works,' caution is in order, as these claims are often false. Furthermore, claims providing very high rates of success are often bogus." And to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Ferozan Mast

Read more from the original source:
Never Take This After Age 50, Warn Pharmacists Eat This Not That - Eat This, Not That

Jeffrey D. Gross, MD, a Neurosurgeon with SPINE and ReCELLebrate – Pro News Report

Get to know Neurosurgeon Dr. Jeffrey D. Gross, who serves patients throughout the States of California and Nevada and beyond.

(ProNewsReport Editorial):- New York City, New York Jun 8, 2022 (Issuewire.com)A board-certified and fellowship-trained neurosurgeon, Dr. Gross is the Owner of SPINE, and a regenerative medicine practice called ReCELLebrate, is seeing patients in Orange County, California, and in Henderson, Nevada, as well as remotely by computer video conference. In his practice, he offers specialized precision and concierge treatment options for patients with neck and/or back problems, as well as brain and head injuries. He provides a comprehensive approach to evaluating the pain generators of the spine and associated areas, and digs deeper to find the source of the problem when identifying the root issues of persistent pain and injuries. Dr. Gross employs regenerative medicine and other non-surgical options first and foremost. He is an internationally recognized expert in these fields.

As a leader in the fields of neurosurgery and stem cell medicine, he commonly treats other physicians and many patients with severe and complex spinal problems. He continually strives to find non-surgical treatments to conservatively assist with the resolution of the problems he identifies in each of his individual patients. In the event that non-surgical treatments are found to be inadequate, he approaches treatment options from the least invasive surgery first. Because of his methodology, he is frequently sought out to provide second opinions prior to many surgeries. He has authored numerous book chapters, and medical journal articles, and is in the process of completing his first book, Young Again, a practical how-to take anti-aging action for anyone. Dr. Gross has written and spoken internationally on regenerative medicine for the spine, and anti-aging. He has been awarded top doctor and best neurosurgeon awards.

A 1992 graduate of the George Washington University School of Medicine and Health Sciences, Dr. Gross went on to complete his internship and residency in neurosurgery at the University of California, Irvine in 1997. Finally, he completed his fellowship in spinal biomechanics and chief residency in neurological surgery at the University of New Mexico in 1999. He is a medical philanthropist and a perennial champion of patient needs over health insurance hassles and denials.

He has been recognized as a Fellow of the American Academy of Neurological Surgeons (FAANS), the doctor is board-certified in neurosurgery through the American Board of Neurological Surgery (ABNS), and is an active member of the Congress of Neurological Surgeons, and the North American Spine Society.

Neurosurgery is the medical specialty concerned with the prevention, diagnosis, surgical treatment, and rehabilitation of disorders that affect any portion of the nervous system including the brain, spinal cord, peripheral nerves, and extra-cranial cerebrovascular system. Neurosurgeons are doctors who diagnose and treat problems with the nervous system, often by performing surgery on the brain or spine. They treat strokes, tumors, certain types of birth defects, infections, and head or spinal cord injuries Dr. Gross applies conservative, non-surgical, and regenerative stem cell medicine options to first try to avoid surgery.

Learn More about Dr. Jeffrey D. Gross:Through his findatopdoc profile, https://www.findatopdoc.com/doctor/1363614-Jeffrey-Gross-Neurosurgeon, or through SPINE, https://ifixspines.com/about-dr-jeffrey-d-gross-md/, or ReCELLebrate, https://recellebrate.com/.

About FindaTopDoc.comFindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

Originally posted here:
Jeffrey D. Gross, MD, a Neurosurgeon with SPINE and ReCELLebrate - Pro News Report

Radium was once cast as an elixir of youth. Are todays ideas any better? – Popular Science

From cities in the sky to robot butlers, futuristic visions fill the history ofPopSci. In theAre we there yet?column we check in on progress towards our most ambitious promises. Read the series and explore all our 150th anniversary coveragehere.

In 1923, Popular Science reported that people were drinking radium-infused water in an attempt to stay young. How far have we come to a real (and non-radioactive) cure for aging?

From the time Marie Curie and her husband Pierre discovered radium in 1898, it was quickly understood that the new element was no ordinary metal. When the Curies finally isolated pure radium from pitchblende (a mineral ore) in 1902, they determined that the substance was a million times more radioactive than uranium. At the time, uranium was already being used in medicine to X-ray bones and even treat cancer tumors, a procedure first attempted in 1899 by Tage Sjogren, a Swedish doctor. Coupled with radiums extraordinary radioactivity and unnatural blue glow, the mineral was soon touted as a cure for everything including cancer, blindness, and baldness, even though radioactivity had only been used to treat malignant tumors. As Popular Science reported in June 1923, it was even believed that a daily glassful of radium-infused water would restore youth and extend life, making it the latest in a long line of miraculous elixirs.

By May 1925 The New York Times was among the first to report cancer cases linked to radium. Two years later, five terminally ill women, who became known as the Radium Girls, sued the United States Radium Corporation where they had worked, hand-painting various objects with the companys poisonous pigment. As more evidence emerged of radiums carcinogenic effects, its cure-all reputation quickly faded, although it would take another half-century before the last of the luminous-paint processing plants was shut down. Radium is still used today in nuclear medicine to treat cancer patients, and in industrial radiography to X-ray building materials for structural defectsbut its baseless status as a life-extending elixir was short-lived.

And yet, radiums downfall did not end the true quest for immortality: Our yearning for eternal youth continues to inspire a staggering range of scientifically dubious products and services.

Since the early days of civilization, when Sumerians etched one of the first accounts of a mortal longing for eternal life in the Epic of Gilgamesh on cuneiform tablets, humans have sought a miracle cure to defy aging and defer death. Five thousand years ago in ancient Egypt, priests practiced corpse preservation so a persons spirit could live on in its mummified host. Fortunately, anti-aging biotech has advanced from mummification and medieval quests for the fountain of youth, philosophers stone, and holy grail, as well as the perverse practices of sipping metal-based elixirs, bathing in the blood of virgins, and even downing Radium-infused water in the early 20th century. But what hasnt changed is that the pursuit of eternal youth has largely been sponsored by humankinds wealthiest citizens, from Chinese emperors to Silicon Valley entrepreneurs.

Weve all long recognized that aging is the greatest risk factor for the overwhelming majority of chronic diseases, whether it be Alzheimers disease, cancer, osteoporosis, cardiovascular diseases, or diabetes, says Nathan LeBrasseur, co-director of The Paul F. Glenn Center for Biology of Aging Research at the Mayo Clinic in Minnesota. But weve really kind of said, well, theres nothing we can do about senescence [cellular aging], so lets move on to more prevalent risk factors that we think we can modify, like blood pressure or high lipids. In the last few decades, however, remarkable breakthroughs in aging research have kindled interest and opened the funding spigots. Fortunately, the latest efforts have been grounded in more established scienceand scientific methodsthan was available in radiums heyday.

In the late 19th century, just as scientists began zeroing in on germs with microscopes, evolutionary biologist August Weismann delivered a lecture on cellular aging, or senescence. The Duration of Life (1881) detailed his theory that cells had replication limits, which explained why the ability to heal diminished with age. It would take 80 years to confirm Weismanns theory. In 1961, biologists Leonard Hayflick and Paul Moorhead observed and documented the finite lifespan of human cells. Another three decades later, in 1993, Cynthia Kenyon, a geneticist and biochemistry professor at the University of California, San Francisco, discovered how a specific genetic mutation in worms could double their lifespans. Kenyons discovery gave new direction and hope to the search for eternal youth, and wealthy tech entrepreneurs were eager to fund the latest quest: figuring out how to halt aging at the cellular level. (Kenyon is now vice president of Calico Research Labs, an Alphabet subsidiary.)

Weve made such remarkable progress in understanding the fundamental biology of aging, says LeBrasseur. Were at a new era in science and medicine, of not just asking the question, what is it about aging that makes us at risk for all these conditions? But also is there something we can do about it? Can we intervene?

In modern aging research labs, like LeBrasseurs, the focus is to tease apart the molecular mechanisms of senescence and develop tools and techniques to identify and measure changes in cells. The ultimate goal is to discover how to halt or reverse the changes at a cellular level.

But the focus on the molecular mechanisms of aging is not new. In his 1940 book, Organisers and Genes, theoretical biologist Conrad Waddington offered a metaphor for a cells life cyclehow it grows from an embryonic state to something specific. In Waddingtons epigenetic landscape, a cell starts out in its unformed state at the top of a mountain with the potential to roll downhill in any direction. After encountering a series of forks, the cell lands in a valley, which represents the tissue it becomes, like a skin cell or a neuron. According to Waddington, epigenetics are the external mechanisms of inheritanceabove and beyond standard genetics, such as chemical or environmental factorsthat lead the cell to roll one way or another when it encounters a fork. Also according to Waddington, who first proposed the theory of epigenetics, once the cell lands in its valley, it will remain there until it diesso, once a skin cell, always a skin cell. Waddington viewed cellular aging as a one-way journey, which turns out to be not so accurate.

We know now that even cells of different types keep changing as they age, says Morgan Levine, who until recently led her own aging lab at the Yale School of Medicine, but is now a founding principal investigator at Altos Labs, a lavishly funded startup. The [Waddington] landscape keeps going. And the new exciting thing is reprogramming, which shows us that you can push the ball back the other way.

Researchers like Levine continue to discover new epigenetic mechanisms that can be used to not only determine a cells age (epigenetic or biological clock) but also challenge Waddingtons premise that a cells life is one way. Cellular reprogramming is an idea first attempted in the 1980s and later advanced by Nobel Prize recipient Shinya Yamanaka, who discovered how to revert mature, specialized cells back to their embryonic, or pluripotent, state, enabling them to start fresh and regrow, for instance, into new tissue like liver cells or teeth.

I like to think of the epigenome as the operating system of a cell, Levine explains. So more or less all the cells in your body have the same DNA or genome. But what makes the skin cell different from a brain cell is the epigenome. It tells a cell which part of the DNA it should use thats specific to it. In sum, all cells start out as embryonic or stem cells, but what determines a cells end state is the epigenome.

Theres been a ton of work done with cells in a dish, Levine adds, including taking skin cells from patients with Alzheimers disease, converting them back to stem cells, and then into neurons. For some cells, you dont always have to go back to the embryonic stem cell, you can just convert directly to a different cell type, Levine says. But she also notes that what works in a dish is vastly different from what works in living specimens. While scientists have experimented with reprogramming cells in vivo in lab animals with limited success, the ramifications are not well understood. The problem is when you push the cells back too far [in their life cycle], they dont know what theyre supposed to be, says Levine. And then they turn into all sorts of nasty things like teratoma tumors. Still, shes hopeful that many of the problems with reprogramming may be sorted out in the next decade. Levine doesnt envision people drinking cellular-reprogramming cocktails to stave off agingat least not in the foreseeable futurebut she does see early-adopter applications for high-risk patients who, lets say, can regrow their organs instead of requiring transplants.

While the quest for immortality is still funded largely by the richest of humans, it has morphed from the pursuit of mythical objects, miraculous elements, and mystical rituals to big business, raising billions to fund exploratory research. Besides Calico and Altos Labs (funded by Russian-born billionaire Yuri Milner and others), theres Life Biosciences, AgeX Therapeutics, Turn Biotechnologies, Unity Biotechnology, BioAge Labs, and many more, all founded in the last decade. While theres considerable hype for these experimental technologies, any actual products and services will have to be approved by regulatory agencies like the Food and Drug Administration, which did not exist when radium was being promoted as a cure-all in the US.

While were working on landing long-term moon shots like editing genomes with CRISPR and reprogramming epigenomes to halt or reverse aging, LeBrasseur sees near-term possibilities in repurposing existing drugs to prop up senescent cells. When a cell gets old and damaged, it has one of three choices: to succumb, in which case it gets flushed from the system; to repair itself because the damage is not so bad; or to stop replicating and hang around as a zombie cell. Not only do [zombie cells] not function properly, explains LeBrasseur, but they secrete a host of very toxic molecules known as senescence associated secretory phenotype, or SASP. Those toxic molecules trigger inflammation, the precursor to many diseases.

It turns out there are drugs, originally targeted at other diseases, that are already in anti-aging trials because theyve shown potential to impact cell biology at a fundamental level, effectively staving off senescence. Although rapamycin was originally designed to suppress the immune system in organ transplant patients, and metformin to assist diabetes patients, both have shown anti-aging promise. When you start looking at data from an epidemiological lens, you recognize that these individuals [like diabetes patients taking metformin] often have less cardiovascular disease, notes LeBrasseur. They also have lower incidence of cancer, and theres some evidence that they may even have lower incidence of Alzheimers disease. Even statins (for cardiovascular disease) and SGL2 inhibitors (another diabetes drug) are being explored for a possible role in anti-aging. Of course, senescence is not all bad. It plays an important role, for example, as a protective mechanism against the development of malignant tumorsso tampering with it could have its downsides. Biology is so smart that weve got to stay humble, right? says LeBrasseur.

Among other things, the Radium Girls taught us to avoid the hype and promise of new and unproven technologies before the pros and cons are well understood. Weve already waited millennia for a miracle elixir, making some horrific choices along the way, including drinking radioactive water as recently as a century ago. The 21st century offers its own share of anti-aging quackery, including unregulated cosmetics, questionable surgical procedures, and unproven dietary supplements. While we may be closer than weve ever been in human history to real solutions for the downsides of aging, there are still significant hurdles to overcome before we can reliably restore youth. It will take years or possibly decades of research, followed by extensive clinical trials, before todays anti-aging research pays dividendsand even then its not likely to come in the form of a cure-all cocktail capable of bestowing immortality. In the meantime, LeBrasseurs advice is simple for those who can afford it: You dont have to wait for a miracle cure. Lifestyle choices like physical activity, nutritional habits, and sleep play a powerful role on our trajectories of aging. You can be very proactive today about how well you age. Unfortunately, not everyone has the means to follow LeBrasseurs medical wisdom. But the wealthiest among usincluding those funding immortalitys questmost definitely do.

See the original post here:
Radium was once cast as an elixir of youth. Are todays ideas any better? - Popular Science

Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical…

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will present at the Biotechnology Innovation Organization (BIO) Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022. His presentation will be primarily focused on the recent clinical updates on nasal administration of foralumab, a fully human anti-CD3 monoclonal antibody, for treatment of patients with secondary progressive multiple sclerosis. He will also provide an update on the initiation of Phase 1b trial with first-ever oral capsules of foralumab for treatment of patients with mild-to-moderately active Crohns Disease. Company management will also be participating in one-on-one meetings throughout the conference.

Presentation Information

Presenter: Kunwar Shailubhai, Ph.D., Chief Executive Officer and Chief Scientific Officer, Tiziana Life SciencesTitle: Enabling Breakthrough Immunotherapies via Novel Routes of Drug Delivery

Day: Tuesday, June 14thTime: 2:00- 2:15 pm PDTLocation: Theater 1

To register for the conference and schedule a one-on-one meeting with Tiziana Life Sciences management, please visit https://www.bio.org/events/bio-international-convention/registration.

Dr. Shailubhai will also attend the BioNJ 29th Annual Dinner Meeting and Innovation Celebration, gathering and honoring members of New Jerseys life science ecosystem, on Thursday, June 9, 2022 at 4:45 pm EDT. This meeting, taking place at the Hilton in East Brunswick New Jersey, was originally planned for February, and was postponed due to the surge of the Omicron variant.

About BIO and the BIO International ConventionThe Biotechnology Innovation Organization (BIO) is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. Our mission is to be the champion of biotechnology and the advocate for our member organizationsboth large and small. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. We also represent state and regional biotech associations, service providers to the industry and academic centers. Currently there are over 3,000+ international and domestic companies registered to attend BIO 2022 across the biotech industry.

About BioNJFounded in 1994, BioNJ, the New Jersey partner of BIO, has been hard at work in its mission to enhance the climate for life sciences in the State. As the representative of an industry that has the potential to change the course of human health, make our environment cleaner and the foods we eat safer and healthier, BioNJ is single-minded in its commitment to the growth and prosperity of this industry within the state of New Jersey.

About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tizianas innovative intranasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tizianas two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tizianas technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further information please contact:

Tiziana Life Sciences:Hana Malik, Business Development and Investor Relations Manager +44 (0) 207 495 2379email:info@tizianalifesciences.com

United States:

Investors:Irina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

The rest is here:
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical...

Microbiome Insights awarded Innovative Solutions Canada contract by Health Canada to enhance regulatory testing for microbial biotechnology products -…

Need for a more reliable, accurate and cost-efficient testing platform

VANCOUVER, BC, June 7, 2022 /PRNewswire/ - Microbiome Insights, Inc., a global leader for end-to-end microbiome sequencing and comprehensive bioinformatic analysis,announced today it was awarded an $881,000 contract from Health Canada to develop a testing platform to accurately identify and characterize micro-organisms found in microbial biotechnology products, and predict their interactions that could mask or enhance adverse effects to determine risks to human and environmental health. This contract follows an initial agreement completed in 2021 and is part of Innovative Solutions Canada, a competitive federal funding program for innovators and federal agencies to collaborate and further commercialize new technology.

"Leveraging our expertise in metagenomics and metatranscriptomics, we are excited to continue our collaboration with Health Canada to develop a testing platform that will benefit both regulators and the manufacturers of microbial mixture products," said Dr. Pedro Dimitriu, the Head of Research and Development at Microbiome Insights. "The translation of microbiome science into products is accelerating and with this, there is a real need for a more reliable, accurate and cost-efficient way to determine the quality and safety of these new products."

Products with microbial mixtures have the capacity to perform novel and complex tasks in a diverse array of biotechnology applications, many of which support the goals of sustainability. The testing required for regulatory approval of these products can be costly, often relying on animal testing to understand their toxicity. There are no suitable test methodologies and novel approaches to determine the adverse effects of microbial mixtures.

As part of the Innovative Solutions Canada program, Microbiome Insights is developing a more reliable, accurate, and cost-efficient way to determine the quality and safety of these new products.

About Microbiome Insights Inc.

Microbiome Insights, Inc. is a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatics analysis. The company is headquartered in Vancouver, Canada, where samples from around the world are processed in its College of American Pathologists (CAP) accredited laboratory. Working with clients from pharma, biotech, nutrition, cosmetic and agriculture companies, and world-leading academic and government research institutions, Microbiome Insights has supported over 700 microbiome studies, from basic research to commercial R&D and clinical trials. The company's expert bioinformaticians and data scientists deliver industry-leading insights, including biomarker discovery, machine-learning-based modelling and customized bioinformatics analysis.www.microbiomeinsights.com

Health Canada

Health Canada is the Federal department responsible for helping Canadians maintain and improve their health. It ensures that high-quality health services are accessible and works to reduce health risks. Health Canada is committed to improving the lives of all of Canada 's people and to making this country's population among the healthiest in the world as measured by longevity, lifestyle, and effective use of the public health care system.www.canada.ca/en/health-canada.html

Innovative Solutions Canada

Innovative Solutions Canada (ISC) is a competitive federal funding program for innovators and federal agencies to collaborate and further commercialize new technology. It is a key component of the Canadian government's Innovation and Skills Plan, a multi-year plan to make Canada a global innovation leader and prepare Canadians to succeed in tomorrow's economy. http://www.ic.gc.ca/eic/site/101.nsf/eng/home

SOURCE Microbiome Insights

Go here to read the rest:
Microbiome Insights awarded Innovative Solutions Canada contract by Health Canada to enhance regulatory testing for microbial biotechnology products -...

NCERC Celebrates the Passing of the Illinois Industrial Biotechnology Partnership Act – RiverBender.com

Megan Wieser

June 4 2022 7:40 AM| updated June 6 2022 1:48 PM

Listen to this article

EDWARDSVILLE On Friday, May 27, the Illinois Industrial Biotechnology Partnership Act was signed into law by Governor JB Pritzker and establishes the Industrial Biotechnology Public-Private Partnership as a State-sponsored board consisting of specified members to promote and market Illinois as a destination for research, development and commercialization for industrial biotechnology.

The National Corn-to-Ethanol Research Center (NCERC) at Southern Illinois University Edwardsville has been a leading institution for research in industrial biotechnology in Illinois and the United States since its doors opened in 2003. Today, it celebrates the signing of this historic legislation.

Don't miss our top stories and need-to-know news everyday in your inbox.

The bill was passed unanimously by both the Illinois House of Representatives and the Illinois Senate with bipartisan support. The Partnership will consist of 12 members, including the Illinois Department of Agriculture, Illinois Department of Commerce and Economic Opportunity, Illinois Department of Labor, NCERC, and several other Illinois-based research organizations and companies that serve the biotechnology sector. The members of the Partnership will lead in leveraging Illinois existing assets and building incentives to attract new companies to the state to perform research and establish manufacturing facilities.

The passing of Illinois Senate Bill 1693 is a significant step in the right direction for providing the support and incentives companies need to bring their biotechnology businesses to the state of Illinois, said NCERC Executive John Caupert. Now, centers like NCERC will be part of a network with a singular mission to attract more economic growth for our state. This activity will bring in more tax dollars, jobs, and other critical components to establish a burgeoning industry in Illinois.

Article continues after sponsor message

NCERC serves companies in the private sector through contractual research services and has helped to commercialize more than 80 technologies that are now in the commercial marketplace, contributing to tens of thousands of jobs and more than $7 billion of annual revenue. By attracting clients from across the globe to perform research at its facility in SIUEs University Park, it also draws hundreds of thousands of dollars in revenue for the nearby hospitality industry. In addition to economic benefits, NCERCs research in biotechnology also supports a variety of workforce training programs by providing hands-on learning opportunities to college students and recent graduates. Since 2014, hundreds of employees who have passed through NCERC on their career paths have found gainful employment in the private sector.

To learn more about NCERC, visit EthanolResearch.com.

About NCERC

The NCERC at SIUE is a nationally recognized research center dedicated to the development and commercialization of biotechnologies. Their unique research laboratories house bench- to demonstration-scale bioreactors and pretreatment and downstream processing equipment, making it the perfect partner to companies in the biotechnology industry. Through their contractual research services, NCERC has played an instrumental role in commercializing more than eighty products that are now used in the commercial marketplace. In addition to its research and development services, NCERC leverages its experienced staff and unique facility to provide a variety of workforce training and education initiatives to train the next generation of bioeconomy professionals. For more information, contact Jackie Hayes at jhayes@ethanolresearch.com, or visit http://www.EthanolResearch.com.

Here is the original post:
NCERC Celebrates the Passing of the Illinois Industrial Biotechnology Partnership Act - RiverBender.com

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting – Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients with hormone receptor positive, HER2-negative, HER2-mutant metastatic breast cancer, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in person from June 3-7 in Chicago, IL, and online. The poster, entitled Neratinib + fulvestrant + trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): outcomes and biomarker analysis from the SUMMIT trial, was presented at the Breast Cancer -- Metastatic Poster Session (poster #1028) by Komal L. Jhaveri, MD, FACP, Medical Oncologist at Memorial Sloan Kettering Cancer Center on June 6 at 9:00 a.m. ET.

Earlier genomic analyses from a cohort treated with a combination of neratinib and fulvestrant suggest that resistance to neratinib may occur via mutant allele amplification or secondary HER2 mutations. The addition of trastuzumab to the combination of neratinib and fulvestrant in this trial demonstrated positive durable responses in patients with HR-positive, HER2-mutant MBC who had received prior CDK4/6 inhibitors (CDK4/6i).

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that included a cohort evaluating the efficacy of the triplet combination of neratinib (N), plus fulvestrant (F), plus trastuzumab (T), in patients with HR-positive, HER2-negative, HER2-mutant metastatic breast cancer, as identified by local genomic sequencing, who had previously received CDK4/6 inhibitors. In order to confirm the contribution of neratinib to the combination, a small, randomized cohort comparing neratinib plus fulvestrant plus trastuzumab versus fulvestrant plus trastuzumab versus fulvestrant was also included. A range of HER2 allelic variants was represented in the cohort. Patients who received the triplet regimen were enrolled in the non-randomized cohort and received 240 mg of neratinib per day intramuscularly, 500 mg intravenous fulvestrant on days 1 and 15 of Cycle 1 and then every 4 weeks, 8mg/kg body weight trastuzumab initially and then 6mg/kg every 3 weeks. Patients in the randomized cohort received either a combination of neratinib, fulvestrant, and trastuzumab, or fulvestrant and trastuzumab, or fulvestrant alone in a 1:1:1 ratio. To counter the side effects of diarrhea, loperamide prophylaxis was mandatory for the first two treatment cycles. Patients who were randomized to the combination of fulvestrant and trastuzumab, or fulvestrant alone, could cross over to receive neratinib, fulvestrant, and trastuzumab at progression. Efficacy was assessed using objective response rate (ORR) and clinical benefit rate (CBR). Tumor tissue was retrospectively assessed by central next-generation sequencing (NGS).

The table below summarizes the efficacy of SUMMIT MBC patients who received neratinib plus fulvestrant plus trastuzumab, those who received fulvestrant plus trastuzumab, and those who received fulvestrant alone; and also those who received fulvestrant plus trastuzumab or fulvestrant and then crossed over to neratinib plus fulvestrant plus trastuzumab upon progression. Patients who received neratinib plus fulvestrant plus trastuzumab (non-randomized + randomized) had a 35.3% investigator-assessed objective response rate, 14.3-month duration of response, 41.7% clinical benefit rate, and 8.2-month median progression-free survival. Neratinib appears to be a critical component of the combination therapy, as demonstrated by lack of response in the small cohort of patients treated with fulvestrant or fulvestrant plus trastuzumab, and by response in a subset of those patients upon crossover to neratinib plus fulvestrant plus trastuzumab.

Table: Efficacy Findings from HR+ Metastatic Breast Cancer Patients

Non-randomized +

Randomized

After crossover

Randomized

After crossover

Randomized HR+

HR+

from F+T to

HR+

from F to N+F+T

Prior CDK4/6i

Prior CDK4/6i

N+F+T

Prior CDK4/6i

(N+F+T, n=51)

(F+T, n=7)

(n=4)

(F, n=7)

(n=6)

18 (35.3)

0

1 (25.0)

0

2 (33.3)

1 (2.0)

0

0

0

0

17 (33.3)

0

1 (25.0)

0

2 (33.3)

Best overall response*

25 (49.0)

0

1 (25.0)

0

2 (33.3)

14.3 (6.4NE)

No response

6.2 (NENE)

No response

6.3 (6.26.4)

24 (47.1)

0

1 (25.0)

0

5 (83.3)

8.2 (4.712.7)

3.9 (1.94.1)

8.25 (NENE)

4.1 (1.64.1)

NE

These results suggest that the combination of neratinib, fulvestrant, and trastuzumab together is promising for treating HR+ and HER2-mutated MBC with prior exposure to CDK4/6i across a range of HER2 mutations.

Dr. Jhaveri, an investigator of the trial, said, Patients with hormone receptor-positive, HER2-negative, HER2-mutant metastatic breast cancer who had received prior treatment with CDK4/6 inhibitors demonstrated encouraging clinical activity with durable responses when treated with the triplet combination of neratinib with fulvestrant and trastuzumab. These responses were observed in patients whose tumors harbored a wide spectrum of HER2 mutations, including those with co-occurring HER3 mutations, regardless of ductal or lobular histology, and with a range of HER2 protein expression.

Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers. We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

Important Safety Information Regarding NERLYNX (neratinib) U.S. Indication

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

DRUG INTERACTIONS:

See the original post:
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting - Business Wire

Animal Health Biotechnology Market 2022- Analysis and In-Depth Research on Market Size, Trends, Emerging Growth Factors and Forecast To 2030 – Digital…

The new report on Animal Health Biotechnology Market Report 2022 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2030 offered by Market Research, Inc. includes a comprehensive analysis of the market size, geographical landscape along with the revenue estimation of the industry. In addition, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Animal Health Biotechnology Market.

Biotechnology utilized in animal healthcare dates back to 19th century when the first vaccines were prepared for its use in animals. Considerable progress in the animal health biotechnology took place recently when biotechnology applications were utilized in both detecting and treating various infectious and parasitic diseases of animals.

Click the link to get a Sample Copy of the Report: https://www.marketresearchinc.com/request-sample.php?id=115348

This market study covers and analyzes the potential of the global Animal Health Biotechnology industry, providing geometric information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy analysis, opportunities and forecasts. One of the major highpoints of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19 on Animal Health Biotechnology market.

Animal Health Biotechnology Market: Competition Landscape

The Animal Health Biotechnology market report includes information on the product presentations, sustainability and prospects of leading player including: Bayer AG, Merck & Co.Inc., Pfizer Inc., Sanofi, Santa Cruz Biotechnology

Animal Health Biotechnology Market: Segmentation

By Types

By Applications

Animal Health Biotechnology Market: Regional Analysis

All the regional segmentation has been studied based on recent and future trends and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Animal Health Biotechnology market report are North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and Latin America.

Key Benefits of the report:

Ask for Discount: https://www.marketresearchinc.com/ask-for-discount.php?id=115348

Major Points Covered in TOC:

Market Summary: It incorporates six sections, research scope, major producers covered, market segments by type, Animal Health Biotechnology market segments by application, study goals, and years considered.

Market Landscape: Here, the global Animal Health Biotechnology Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances landscape, and most recent patterns, consolidation, development, and segments of the overall industry of top organizations.

Profiles of Companies: Here, driving players of the worldwide Animal Health Biotechnology market are considered dependent on deals region, key items, net income, cost, and creation.

Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income and creation, portion of the overall industry, CAGR and market size by locale. Here, the worldwide Animal Health Biotechnology Market is profoundly examined based on areas and nations like North America, Europe, Asia Pacific, Latin America and the MEA.

Application: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide Animal Health Biotechnology Market.

Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge and creation and creation esteem estimate by type.

Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

Enquiry before buying this premium Report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=115348

Contact Us

Market Research Inc

Author: Kevin

US Address: 51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us: +1 (628) 225-1818

Write Us: [emailprotected]

Here is the original post:
Animal Health Biotechnology Market 2022- Analysis and In-Depth Research on Market Size, Trends, Emerging Growth Factors and Forecast To 2030 - Digital...

Digital Genome Engineering Market Size and Industry Analysis 2022 : Biotechnology Revolution to Boom the Digital Genome Business with Latest Research…

Digital Genome Engineering Market Size and Share is Estimated to Growth by US$ 60.35 at CAGR 11.1% during Forecast period 2028

This press release was orginally distributed by SBWire

Londan, United kingdom (SBWIRE) 06/06/2022 Digital Genome Engineering is a comprehensive digital set of genetic material that occurs in a cell or an organism. It allows experts to get a nearer look at genetic disorders, with instant access to sequence data and tools to resolve unending custom queries. Thus, the aforementioned parameters will augment the market growth. Digital Genome Engineering deals with genes & their functions and assists in finding causes behind chronic disorders and also to resolve them. This technology has sparked a revolt in invention-centred research & systems biology to expedite insight of the most complex genetic systems.

The global Digital Genome Engineering market research report provides an in-depth analysis of the existing and future state of the industry. The study comprises all market data and is based on extensive primary and secondary research. Statistics by type, industry, channel, and other parameters are included in the analysis, as well as market volume and value for each category. The coronavirus pandemic has an influence on the global economy. Several market conditions have shifted. The market is fast evolving, according to the study report, and its influence is being studied both now and in the future.

Get a Sample Report of Digital Genome Engineering Market @ https://www.intelligencemarketreport.com/report-sample/486645

The study offers exact figures for the industry's market size, share, production capacity, demand, and growth for the anticipated year. This is the most recent market effect analysis research for COVID-19. The Digital Genome Engineering market research looks at the market's top businesses, distributors, and the entire structure of the industrial chain. It also evaluates the aspects and criteria that may have an impact on market expansion.

The Major Key Company Profiles included in Digital Genome Engineering market study are:

-Abbott Laboratories-Agilent Technologies Inc-Becton, Dickinson and Company-Biomerieux SA-Bio-rad Laboratories Inc-Roche-Illumina Inc-Inscripta-Oxford Nanopore Technologies Ltd-Pacific Bioscience-Perkinelmer Inc-Qiagen NV-Regeneron Pharmaceuticals-Thermo Fisher Scientific Inc

Market Segmentation

The research looks on the industry's growth goals, cost awareness, and manufacturing procedures. Market segmentation by product type, application, end-user, and geography is discussed in the Digital Genome Engineering research report. A basic industry overview, as well as categorization, definition, and, as a result, the supply and demand chain structure, are included in the market study. Global research includes global marketing data, competitive climate surveys, growth rates, and critical development status information.

Russia-Ukraine War Impact on Digital Genome Engineering Market

The impact of the Russia-Ukraine conflict on the worldwide market is covered in the research study. While tensions between Russia and Ukraine have been increasing for years, the present military action heightens fears of a long-term conflict within Ukraine, as well as market and global economic implications. The market research report covers whether this ongoing conflict is making any of on target market or not.

The Digital Genome Engineering Market Segments and Sub-Segments are Listed Below:

Segmentation by type:

-Miss Target Assessment-Target Efficiency Prediction-Typing Efficiency Prediction-Measurement of Editing Efficiency of Target Genome-Other

Segmentation by application:

-Hospital-Research Institute-Institutions of Higher Learning

Do you have any query regarding this research? Ask your Query @ https://www.intelligencemarketreport.com/send-an-enquiry/486645

Regional Analysis

From production and consumer ratios to market size and market share, import and export ratios, supply and demand, consumer demand ratios, technological advancements, research and development, infrastructure development, economic growth, and a strong market presence in every region, research covers everything. Geographic study will assist players in discovering profitable markets where they may capitalize on fresh opportunities. The Digital Genome Engineering market is divided into five regions: North America, Latin America, Europe, Asia Pacific, and the Rest of the World.

Competitive Outlook

The research report covers financial conditions, global positioning, product portfolios, income and gross profit margins, as well as technology and research breakthroughs. The Digital Genome Engineering market research focuses on the industry's most notable acquisitions, collaborations, and product launches. To provide deeper insights into key players, the study report incorporates modern research approaches such as SWOT and Porter's Five Forces analysis. The study provides a comprehensive assessment of the global competitive climate as well as critical insights into the major competitors and their expansion plans.

Table of Contents Major Key Points

1 Scope of the Report2 Executive Summary3 Digital Genome Engineering Market Size by Player4 Digital Genome Engineering by Regions5 Americas6 APAC7 Europe8 Middle East & Africa9 Market Drivers, Challenges and Trends10 Global Digital Genome Engineering Market Forecast11 Key Players Analysis12 Research Findings and Conclusion

Buy Single User PDF of Digital Genome Engineering Market @ https://www.intelligencemarketreport.com/checkout/486645

About Us:

Intelligence Market Report includes a comprehensive rundown of statistical surveying reports from many distributers around the world. We brag an information base traversing basically every market classification and a much more complete assortment of statistical surveying reports under these classifications and sub-classifications.

Intelligence Market Report offers premium reformist factual looking over, statistical surveying reports, investigation and gauge information for businesses and governments all throughout the planet.

For more information on this press release visit: http://www.sbwire.com/press-releases/digital-genome-engineering-market-size-and-industry-analysis-2022-biotechnology-revolution-to-boom-the-digital-genome-business-with-latest-research-development-1358631.htm

More here:
Digital Genome Engineering Market Size and Industry Analysis 2022 : Biotechnology Revolution to Boom the Digital Genome Business with Latest Research...

Hand Anatomy – eOrthopod.com

Introduction

Few structures of the human anatomy are as unique as the hand. The hand needs to be mobile in order to position the fingers and thumb. Adequate strength forms the basis for normal hand function. The hand also must be coordinated to perform fine motor tasks with precision. The structures that form and move the hand require proper alignment and control in order for normal hand function to occur.

In addition to reading this article, be sure to watch our Hand Anatomy Animated Tutorial Video.

This guide will help you understand

The important structures of the hand can be divided into several categories. These include

The front, or palm-side, of the hand is referred to as the palmar side. The back of the hand is called the dorsal side.

Bones and Joints

There are 27 bones within the wrist and hand. The wrist itself contains eight small bones, called carpals. The carpals join with the two forearm bones, the radius and ulna, forming the wrist joint. Further into the palm, the carpals connect to the metacarpals. There are five metacarpals forming the palm of the hand. One metacarpal connects to each finger and thumb. Small bone shafts called phalanges line up to form each finger and thumb.

The main knuckle joints are formed by the connections of the phalanges to the metacarpals. These joints are called the metacarpophalangeal joints (MCP joints). The MCP joints work like a hinge when you bend and straighten your fingers and thumb.

The three phalanges in each finger are separated by two joints, called interphalangeal joints (IP joints). The one closest to the MCP joint (knuckle) is called the proximal IP joint (PIP joint). The joint near the end of the finger is called the distal IP joint (DIP joint). The thumb only has one IP joint between the two thumb phalanges. The IP joints of the digits also work like hinges when you bend and straighten your fingers and thumb.

The joints of the hand, fingers, and thumb are covered on the ends with articular cartilage. This white, shiny material has a rubbery consistency. The function of articular cartilage is to absorb shock and provide an extremely smooth surface tofacilitate motion. There is articular cartilage essentially everywhere that two bony surfaces move against one another, or articulate.

Ligaments and Tendons

Ligaments are tough bands of tissue that connect bones together. Two important structures, called collateral ligaments, are found on either side of each finger and thumb joint. The function of the collateral ligaments is to prevent abnormal sideways bending of each joint.

In the PIP joint (the middle joint between the main knuckle and the DIP joint), the strongest ligament is the volar plate. This ligament connects the proximal phalanx to the middle phalanx on the palm side of the joint. The ligament tightens as the joint is straightened and keeps the PIP joint from bending back too far (hyperextending). Finger deformities can occur when the volar plate loosens from disease or injury.

The tendons that allow each finger joint to straighten are called the extensor tendons. The extensor tendons of the fingers begin as muscles that arise from the backside of the forearm bones. These muscles travel towards the hand, where they eventually connect to the extensor tendons before crossing over the back of the wrist joint. As they travel into the fingers, the extensor tendons become the extensor hood. The extensor hood flattens out to cover the top of the finger and sends out branches on each side that connect to the bones in the middle and end of the finger.

The place where the extensor tendon attaches to the middle phalanx is called the central slip. When the extensor muscles contract, they tug on the extensor tendon and straighten the finger. Problems occur when the central slip is damaged, as can happen with a tear.

Muscles

Many of the muscles that control the hand start at the elbow or forearm. They run down the forearm and cross the wrist and hand. Some control only the bending or straightening of the wrist. Others influence motion of the fingers or thumb. Many of these muscles help position and hold the wrist and hand while the thumb and fingers grip or perform fine motor actions.

Most of the small muscles that work the thumb and pinky finger start on the carpal bones. These muscles connect in ways that allow the hand to grip and hold. Two muscles allow the thumb to move across the palm of the hand, an important function called thumb opposition.

The smallest muscles that originate in the wrist and hand are called the intrinsic muscles. The intrinsic muscles guide the fine motions of the fingers by getting the fingers positioned and holding them steady during hand activities.

Nerves

All of the nerves that travel to the hand and fingers begin together at the shoulder: the radial nerve, the median nerve, and the ulnar nerve. These nerves carry signals from the brain to the muscles that move the arm, hand, fingers, and thumb. The nerves also carry signals back to the brain about sensations such as touch, pain, and temperature.

The radial nerve runs along the thumb-side edge of the forearm. It wraps around the end of the radius bone toward the back of the hand. It gives sensation to the back of the hand from the thumb to the third finger. It also supplies the back of the thumb and just beyond the main knuckle of the back surface of the ring and middle fingers.

The median nerve travels through a tunnel within the wrist called the carpal tunnel. This nerve gives sensation to the thumb, index finger, long finger, and half of the ring finger. It also sends a nerve branch to control the thenar muscles of the thumb. The thenar muscles help move the thumb and let you touch the pad of the thumb to the tips each of each finger on the same hand, a motion called opposition.

The ulnar nerve travels through a separate tunnel, called Guyons canal. This tunnel is formed by two carpal bones, the pisiform and hamate, and the ligament that connects them. After passing through the canal, the ulnar nerve branches out to supply feeling to the little finger and half the ring finger. Branches of this nerve also supply the small muscles in the palm and the muscle that pulls the thumb toward the palm.

The nerves that travel to the hand are subject to problems. Constant bending and straightening of the wrist and fingers can lead to irritation or pressure on the nerves within their tunnels and cause problems such as pain, numbness, and weakness in the hand, fingers, and thumb.

Blood Vessels

Traveling along with the nerves are the large vessels that supply the hand with blood. The largest artery is the radial artery that travels across the front of the wrist, closest to the thumb. The radial artery is where the pulse is taken in the wrist. The ulnar artery runs next to the ulnar nerve through Guyons canal (mentioned earlier). The ulnar and radial arteries arch together within the palm of the hand, supplying the front of the hand, fingers, and thumb. Other arteries travel across the back of the wrist to supply the back of the hand, fingers, and thumb.

The hand is formed of numerous structures that have an important role in normal hand function. Conditions that change the way these structures work can greatly impact whether the hand functions normally. When our hands are free of problems, its easy to take the complex anatomy of the hand for granted.

Read the original post:
Hand Anatomy - eOrthopod.com

Grey’s Anatomy season 19 premiere date: When will news come out? – CarterMatt

We are almost two weeks removed now from the end of season 18 and, of course, we want to know more aboutGreys Anatomyseason 19! When is the next season of the landmark drama going to come out?

It goes without saying, but there is a lot to be excited for as we ponder over the future of this show. Take, for starters, the fact that there were multiple cliffhangers that hint at a very uncertain future for a number of familiar faces. Teddy and Owen, for example, could be in a different part of the world after fleeing Seattle. Meanwhile, Bailey quit her job after the residency program was shut down! All of a sudden, it feels to her like the work she put in more or less amounts to nothing.

Rest assured,Greys Anatomyseason 19 is on the fall schedule for ABC, and we will probably have a chance to get more news on it sooner rather than later. Just how long are we talking here? If we were to guess, the news will start pouring in when it comes to the middle of July. This is when weve seen the network announce premiere dates in advance, and there is little reason to think that theyd start changing things up all of a sudden here. They dont want to announce these datestooearly, after all, in fear that they would have to change them a little bit later. The most important thing to know is that your favorites are coming back, and they could be bringing some more great stuff across the board with them.

Once the premiere date is announced and filming begins later this summer, its our expectation that come early September, we could start getting a few teases as to what is actually coming up.

Related Be sure to get some more news when it comes to Greys Anatomy right now

Be sure to share right now in the attached comments! Once you do just that, remember to also stay put for other updates you will not want to miss. (Photo: ABC.)

Continue reading here:
Grey's Anatomy season 19 premiere date: When will news come out? - CarterMatt

Anatomy of a controversy: Inside the drama at The Washington Post – Poynter

It didnt start with a retweet.

The controversy currently swirling around The Washington Post doesnt go back days. It goes back years.

If you want to truly understand how one of the most respected news organizations in the world is smack dab in the middle of a hot mess, you cant start with a high-profile reporter retweeting a sexist and homophobic tweet. You have to look at the history of the reporter who objected to that retweet and her relationship with the paper she works for, as well as the inconsistent social media policy of that paper.

And to do all that, you have to go back to at least 2018 when Brett Kavanaugh was a controversial nominee for the Supreme Court, controversial because of allegations of sexual assault and misconduct. Post reporter Felicia Sonmez, a politics breaking news reporter, was told by her editors that she could not cover stories involving Kavanaugh because they felt it was a conflict of interest. How? Because Sonmez had been open and public about being a survivor of sexual assault.

The Posts policy was considered unusual if not unheard of in journalism circles. Even Post media writer Paul Farhi wrote so.

Fast-forward to January 2020 and the day basketball star Kobe Bryant was killed in a helicopter crash. Soon after the news broke and tributes and remembrances poured in about Bryant, Sonmez used her Twitter feed to link to a 2016 Daily Beast story that recalled the 2003 rape allegations against Bryant. Marty Baron, who was the Posts well-known executive editor at the time, put Sonmez on paid administrative leave, saying Sonmez displayed poor judgment that undermined the work of her colleagues.

The leave soon ended after more than 300 Post staffers signed a letter in support of Sonmez.

But by this point, the seeds of resentment between Sonmez and Post leadership had seemingly been planted.

Now lets move to March 2021, when the Post finally reversed its decision and allowed Sonmez to write about stories involving sexual assault. But that decision was reversed only after Sonmez went on Twitter to voice her complaints about the Posts policy.

It came to a head a few months later, in July 2021, when Sonmez sued the Post and several current and former top editors, alleging that she had suffered discrimination and retaliation. Sonmezs suit said she had lost opportunities for career advancement and had experienced economic loss, humiliation, embarrassment, mental and emotional distress, and the deprivation of her rights to equal employment opportunities. She also claimed that she was retaliated against for speaking out publicly. (The lawsuit was dismissed in March of this year when a judge ruled that Sonmez had not demonstrated the paper showed discriminatory motive when it banned her from covering stories related to sexual harassment or misconduct. Sonmez is appealing that ruling.)

By this point, the situation was, at best, awkward between the paper and Sonmez. Questionable leadership decisions, including those from the now-retired Baron, a clunky social media policy and a reporter unafraid to go public with her criticism of the paper created a perfect storm that led us to last Friday and the controversy that is now captivating the media world, much to the delight of those who like to slam the so-called mainstream media.

So what happened Friday? Post reporter Dave Weigel retweeted a tweet from a social media personality that said, Every girl is bi. You just have to figure out if its polar or sexual.

Sonmez took a screenshot of the retweet and tweeted, Fantastic to work at a news outlet where retweets like this are allowed!

However, some argue that it wasnt allowed, not at all evidenced by the fact that within an hour of his retweet on Friday, Weigel deleted it and apologized for it, and by Monday was suspended from the paper for a month without pay.

Then again, was it Sonmezs tweet that spurred the Post to take swift action?

This also wasnt the first social media controversy the Post had this year. In a February tweet, Micah Gelman, senior editor and head of Post Video, misidentified Post video technician Breanna Muir as Breonna Taylor, the Black medical worker who was shot and killed by Louisville police officers in March 2020. Gelman apologized publicly and privately. Regarding this latest incident, Muir hit reply all on a staff note from executive editor Sally Buzbee and praised Sonmez for speaking out against harassment, discrimination and sexism.

A month before that, another Post editor, Lori Montgomery, tweeted then deleted a tweet that criticized an SFGate column about retiring Steelers quarterback Ben Roethlisberger. The column called Roethlisberger a jackass and mentioned how Roethlisberger had been accused of rape in the past. Montgomery tweeted, The only interesting thing about this column is how easily disproven and completely FOS it is.

Interestingly, Sonmez called out Montgomerys tweet, tweeting, Respectfully, @loriamontgomery, this @drewmagary column contains facts about sexual assault allegations against Ben Roethlisberger that the Washington Posts own story backs up.

Montgomery was given a verbal warning, and Sonmez has continued to call out on Twitter the inconsistencies of the Posts social media policy.

And so here we are this week with the paper known for the kind of dogged reporting that uncovered the Watergate scandal swept up in a quagmire that has included a suspension, two memos from the executive editor, countless contentious and accusatory tweets and a narrative that the Post has a hostile and toxic work environment. In the week where a House Select Committee investigates the events of Jan. 6 a story for which the Post won a prestigious Pulitzer Prize for Public Service the dominant story about the Post is this soap opera. It was even a topic on Wednesdays The View.

In the past 48 hours, the story has shifted slightly as more and more staffers are defending the Posts workplace and showing frustration with Sonmez not for calling out Weigels inappropriate retweet, but for continuing the conversation about it.

On Wednesday, I spoke to several well-established and respected journalists at the Post, both male and female, who wanted to make it clear: The Washington Post is a good place to work and not the toxic newsroom that this latest controversy might suggest. The Post staffers asked to speak on background and not have their names used, mostly because those who have publicly spoken up for the Post and questioned or challenged Sonmez have come under heavy criticism and been portrayed as insensitive.

I think a lot of people at the Post are frustrated with the way all of this is unfolding, one Post reporter told me. Obviously, a lot of people strongly feel that this doesnt represent the culture at the Post.

This source continued, Its frustrating to have this person make these assertions broadly about the Post and imply and amplify this idea that theres this great division and that the Post has this toxic work environment when that is not the case.

And yet another said it goes well beyond newsroom bickering.

This is affecting sourcing relationships, they said, adding that sources have told them that they are hesitant to talk to the Post right now because of all the drama.

Another staffer, a woman, said they had talked to several female staffers who said they felt Sonmez had taken it too far, but they didnt want to speak out because they didnt want to undermine Sonmez.

Its just an unwinnable situation for everyone involved, the staffer said.

Another unnamed staffer told Vanity Fairs Charlotte Klein, I think Felicia initially was right that was a gross Dave Weigel tweet, and we were all grateful she called attention to it. (The problem was in) continuing to make it an issue and go after more and more colleagues.

Of all the staffers I talked to Wednesday, not one defended Weigels retweet, although one did say they wish Sonmez had taken her complaints to editors and stayed off Twitter. I
t has been reported that Sonmez first complained about Weigels retweet on an internal Slack channel and that National editor Matea Gold, in the same Slack channel, wrote that The Post is committed to maintaining a respectful workplace for everyone and we do not tolerate demeaning language or actions. But Sonmez went to Twitter just minutes after her Slack message.

Over the weekend, Post staffer Jose A. Del Real accused Sonmez on Twitter of repeated and targeted public harassment of a colleague and suggested she was rallying the internet to attack (Weigel) for a mistake.

Buzbee stepped in on Sunday, sending out a brief memo to staff saying they were expected to treat each other with respect and kindness both in the newsroom and online.

One staffer told me Weigel has had a questionable history on social media, so his monthlong suspension might have been for an accumulation of poor decisions. It is also believed Weigel has been suspended once before for his social media use. Post officials would not discuss him or this matter.

Buzbee sent out another memo to staff on Tuesday this one much longer and much more sternly worded, writing in part, We do not tolerate colleagues attacking colleagues either face to face or online. Respect for others is critical to any civil society, including our newsroom. The newsroom social media policy points specifically to the need for collegiality.

Buzbee added, We know it takes bravery to call out problems. And we pledge to openly and honestly address problems brought to us. She also said the Post will update its social media policy.

Meanwhile, Sonmez continued tweeting, including lengthy threads about the Posts social media policy. Sonmez tweeted, In early 2020, @stevenjay and @loriamontgomery, then the Posts National and deputy National editors, commissioned an internal report on social media use in response to newsroom-wide outrage over my suspension. Two years later, nothing has changed.

Washington Post media writer Jeremy Barr wrote, The union that represents Post employees, the Washington Post Guild, has repeatedly lobbied for The Post to update the companys social media policies, which the guild has described as outdated and not sufficiently equitable, and repeated that call on Tuesday.

As Sonmez continued tweeting, Post staffer Lisa Rein tweeted at Sonmez on Tuesday night to Please stop. Sonmez replied, Please stop requesting that tweets from a colleague falsely accusing me of bullying and clout chasing be taken down?

Sonmez then added, Do you have any idea of the torrent of abuse Im facing right now? Sonmez then included screenshots of some of the nasty attacks she has been receiving online.

The social media melee picked up throughout the week with many high-profile staffers defending the Post.

White House bureau chief Ashley Parker tweeted, The Post is not perfect. No institution is. But Im proud to work here. I love coming to work (almost) every single day, and knowing that my colleagues are collegial, collaborative and fun humans not to mention talented journalists who are always striving to do better.

Reporter Amber Phillips tweeted, Working at The Washington Post, Im in awe almost every day how such talented journalists, from all backgrounds, can also be so collegial and thoughtful and caring. I love working here, and I love helping improve it.

Investigative political reporter Josh Dawsey tweeted, no institution is perfect, including the post. but the place is filled with many terrific people who are smart and collegial. im proud to work here.

Those are just a few examples, but there were enough that some wondered if it was a coordinated effort to defend the Post.

But a staffer told me on Wednesday, That was ridiculed by a lot of people as being some kind of contrived messaging operation, but I have no reason to believe it was anything other than an organic expression of how people feel about this newsroom.

Meanwhile, some Post staffers and others in the journalism world took to Twitter to stand by Sonmez, who tweeted, I often hear from colleagues who want to say something but are afraid to speak out. Knowing how the Post punished me for my own trauma and how a colleague publicly accused me of bullying for flagging a sexist tweet I dont blame them for being afraid of retaliation.

Sonmez was referring to her history with the Post.

Look, one staffer told me Wednesday, theres no question she was treated (crappy) in the past by the Post. What they did to her was wrong. But that and whats happening now are two different situations, in my opinion.

Another Post staffer said, That wasnt right, and most everybody I know at the Post was in her corner on that. They handled that poorly.

And some are questioning whether Post leadership is handling this situation as well as it can.

Its a real s show, one staffer said.

The Post is not commenting beyond a statement from Post communications chief Kris Coratti Kelly, who said, While we have not commented publicly, this is being addressed directly with the individuals involved.

When reached Wednesday evening, Sonmez declined to comment.

What can Buzbee do now?

Its a really good question, one staffer said. I dont think theres any really good options here. Theres obviously a lot of hard feelings involving the person who is spearheading this. I dont know how this goes away. But I just want it known that the Post is a good place to work, and I think most of my colleagues feel that way.

Tom Jones is Poynters senior media writer. For the latest media news and analysis, delivered free to your inbox each and every weekday morning, sign up for his Poynter Report newsletter.

Visit link:
Anatomy of a controversy: Inside the drama at The Washington Post - Poynter

Ranking the top ‘Grey’s Anatomy’ episodes of all time – Crow River Media

For 18 seasons Greys Anatomy has been thrilling and breaking the hearts of countless diehard fans. With 401 episodes and counting, the show is currently the longest running primetime medical dramaon television, giving it an outsize impact on American pop culture. Even those who have never seen an episode have probably heard someone reference Dr. McDreamy (a reference to Patrick Dempseys character) or watched one of the many shows creator Shonda Rhimes has helmed since her Greys Anatomy breakout. It may have even changed the way some people view health care and doctors in the real world.

This rich history makes it extremely difficult to narrow down the shows best hours. After all, this is a show thats featured Post-It note weddings, hospital proms, and enough freak accidents to make any sane person think twice before checking into Grey Sloan Memorial Hospital. Heartbreaking departures have allowed the shows diverse cast to explore some of the most pressing social issues of the day, including LGBTQ+ rights and the #MeToo movement, in some of the series most acclaimed storylines. Theres no denying Meredith Greys life has been agonizing, chaotic, and electrifying to watch.

Stacker has taken a more democratic approach to reveal the top 25 best Greys Anatomy episodes, using data from IMDb. Rankings are based on each episodes average IMDb rating, with ties broken by votes. The end result is a list of the best swoon-worthy declarations of love, heartbreaking tragedies, and moving moments of pure friendship that have kept fans glued to screens for more than a decade.

You may also like: 50 best episodes of 'Friends'

See more here:
Ranking the top 'Grey's Anatomy' episodes of all time - Crow River Media

Anatomy of a jacket: how Kathmandu is rethinking sustainable clothing – The Guardian

Winter, as they say, is coming. If youre looking for a puffer jacket to keep yourself warm with a lighter impact on the environment, the team at Kathmandu has been working hard. The New Zealand-founded, certified B-Corp outdoor wear company recently launched its NXT-Level BioDown jacket, an innovative and award-winning piece of clothing made from a highly durable, biodegradable nylon.

While most jackets are made from polyester, Kathmandu chose nylon for its greater durability. It also decided to opt for nylon 66 (commonly used in friction bearings, carpets and luggage), a stronger version of its close cousin, nylon 6 (think toothbrush bristles) so that it will last and be worn longer.

Kathmandus scientists tweaked the polymer with a new ingredient designed to trigger biodegradation in an oxygen-free landfill environment. In a nutshell, the ingredient makes the discarded jacket attract microbes that form a biofilm on the material to help them break down those long chains of polymers. (But dont worry, your jacket wont start falling apart in the wash or while youre walking the dog in the rain only when it reaches oxygen-free landfill.*)

Hang on, isnt nylon derived from fossil fuel? Well, yes. Kathmandus Californian-born general manager of product, Robert Fry, says the decision to use nylon is all about playing the long game: producing a high-quality garment that will last longer, be more recyclable when technology catches up, and, in the meantime, biodegrade in three to five years under the right conditions.*

For us, the long-term goals around sustainability have to do with circularity more than anything else, Fry says from the companys Christchurch headquarters. And there are lots of principles of circularity, all of which were heavily invested in supporting, exploring, developing and innovating around, and theyre all in various states of go.

The problem Kathmandu faces is that much of the infrastructure required to close those circular systems isnt widely available in Australia yet. For example, we are still a long way away from widespread textile-to-textile chemical recycling, and the types of anaerobic, or oxygen-free, landfills required to make BioDowns innovative material biodegrade effectively are sparse.

The hope is that demand will ignite supply. Were doing our part to energise that infrastructure, so that as we introduce new products, new concepts into the marketplace, that theres an infrastructure in place that we can partner with, plug into and collaborate with, Fry says.

So, after youve worn your jacket for years, how does the breakdown of the material eventually happen?

Manu Rastogi, who heads Kathmandus innovation team and worked closely on the BioDown design, says: Biodegradation happens at the molecular level. Nylon 66 is made of carbon, hydrogen, oxygen and nitrogen. Microbes break down those molecular chains, whether that happens over hundreds of years or a few years, as in the case of BioDown. As the nylon is consumed by microbes, they release carbon dioxide and methane, and all that remains at the end is basically microbial poop.

Rastogi and his team went in search of best-practice landfills and found more than 20 biologically active sites in New Zealand. Although there are bioreactor landfills in Australia, our size and system of state governments means theyre not well documented, Rastogi says. Theres room for improvement.

Each state and territory also manages and prioritises waste differently. In suburban Sydney, roughly 40% of waste goes to Veolias Woodlawn Eco Precinct, an innovative, modern landfill facility that includes the necessary bioreactor landfill.

And if you look at whats happening globally, Rastogi says, thats where the landfill design and engineering is going: towards how do we harness carbon dioxide and methane and use that energy to generate electricity, so it doesnt go out in the atmosphere as greenhouse gases?

Adopting the build it and they will come philosophy, Rastogis team designed the jacket to be as recyclable as possible, too, making the zippers and inner lining from the same material. Insulating the jacket are duck down and feathers certified to the Responsible Down Standard, the global standard for ensuring best practices in animal welfare throughout the retail supply chain. And, by scanning in a QR code on the product, customers can trace the key conditions and source of the down in their jacket through the website Track My Down.

Other biodegradable, environmentally friendly details include labels made of cotton, hang tags made out of paper instead of plastic, and using natural bentonite clay instead of silica gel to absorb moisture during shipping.

In an imperfect world, its still vital for consumers and manufacturers to play their role and keep striving for a circular economy.

Fry says: We have to be responsible citizens of the planet and of our respective nations. Its morally incumbent upon us to do our best to make the world a better place. As Manu likes to say, we want to get from a place of doing less bad to doing more good.

Granted, the fully circular economy may be a while off yet, but its encouraging to see at least one company designing end-of-life responsibilities into its products from the very beginning.

Check out Kathmandus new NXT-Level BioDown jacket.

*Testing under ASTM D5511 indicates biodegradation of 86.6% after 3 years could occur in optimal conditions in some biologically active landfills without oxygen. Please ask your local council if this type of collection or waste disposal facilities exist for the product.

Excerpt from:
Anatomy of a jacket: how Kathmandu is rethinking sustainable clothing - The Guardian

The Anatomy of the Celtics’ Fourth-Quarter Comeback in Game 1 of NBA Finals – Sports Illustrated

Notorious for playing with energy and assertiveness that fuels their third-quarter runs, the Warriors did just that in Game 1 of the NBA Finals. They hung 38 points on the league's top-ranked defense while holding the Celtics to 24.

As a result, Golden State, a team yet to lose on its home floor in the playoffs, entered the final frame with a 12-point lead. Boston scored the last points of the third quarter, courtesy of a pair of Derrick White free throws, but a comeback required urgency, and there was little margin for error. Otherwise, the Celtics would spend the days leading into Game 2 kicking themselves for how they came out of the half.

Instead, they met the moment, landing a fourth-quarter haymaker, outscoring the Warriors 40-13 before the hosts added a three after both teams emptied their benches.

Jaylen Brown was at the center of that fourth-quarter takeover, getting them off to the fast start they needed, factoring into Boston's first seven points.

The play below, a three for Brown, also highlights the Celtics hunting Jordan Poole, who they'll target relentlessly throughout these Finals.

The next possession demonstrates a problem Golden State had throughout Thursday's loss and will continue to have difficulty with this series. The Warriors lack high-level perimeter defenders.

As it relates to the following clip, Otto Porter, who played well overall in Game 1, is at a point in his career where it's hard for him to keep up with Jaylen Brown. The result is Brown driving by him, getting into the paint, occupying Klay Thompson's attention, and while Draymond Green knows what's coming, he can't prevent this alley-oop to Robert Williams.

Shortly after that, White attacked Klay Thompson off the dribble, getting deep into the paint. When White pivots, Porter sees him staring towards the left slot, persuading him to break that way before realizing the ball's going to Brown. And with White leading Brown further towards the corner, Brown gets a clean, in-rhythm look at a three that barely grazes the net.

The Celtics' comeback wasn't, nor could it have been, strictly a product of what they were accomplishing offensively. At the other end, Boston went smaller and started switching more frequently. The Celtics' big men also raised their pick-up point, meeting Stephen Curry higher up the floor as he came off screens.

Here, Al Horford's waiting for Curry above the three-point line, a shade below the pick from Kevon Looney. Horford and Jayson Tatum surround Curry, White tags the roller, Looney, and Horford uses his length to stay connected to Curry and Looney. Perhaps the latter could've gotten to the other side of the rim with more urgency, but the pass could still prove difficult. Instead, Curry rises for a floater as Tatum comes across his face to contest the shot.

As for the impact of Boston getting back to its preferred method of defending the pick-and-roll, which is switching on screens, one benefit was getting the ball out of Curry's hands.

In the play below, the Celtics don't switch the off-ball screen, which is really just Green grabbing his defender, Tatum. But when Curry shakes free of White, Tatum has no choice but to jump out to contest his potential shot. That results in Curry swinging the ball to Andrew Wiggins, who's plenty capable of making this three, but the Celtics will live with this shot.

And while Boston's defense was limiting Curry to four points in the final frame, its offense continued driving into the paint, moving the ball around, and chipping away at the deficit.

Here, Brown gets out of the corner and into the paint, prompting Porter to help wall off his drive as his man, White, drifts beyond the arc. Brown's strong with the ball and throws it on a line to White, who drills a right-wing three to bring the Celtics within one.

Scroll to Continue

White, who scored 21 points and was outstanding in this game, continued to play a critical role in Boston's comeback, cashing a three with Curry in his jersey, knotting the score at 103 with 5:40 remaining.

The next time down the floor, the Warriors are slow to match up in transition. Tatum swings the ball to White, who drives baseline off the catch, keeping Porter by the basket. It also forces Wiggins to zone two, accounting for Payton Pritchard and Horford.

The pass to Horford would've been more challenging, but Wiggins is splitting the difference between his two responsibilities, and he's too far in to break up the baseline pass. Pritchard then swings the ball to Horford, who's unbothered by Thompson coming over and getting his hand up, swishing a three to put the Celtics ahead 106-103.

Another instrumental aspect of Boston's comeback win was Golden State living up to its reputation for not taking care of the ball. In the fourth quarter, the Warriors committed four turnovers, two of the live-ball variety, leading to ten points for the Celtics.

And while overall, the hosts were more effective crashing the offensive glass, producing 26 second-chance points compared to 15 by Boston, none of those came in the fourth quarter before both teams emptied their benches. Conversely, as the Celtics rallied, they tacked on six points after securing an offensive rebound.

And with just under a minute to play, Tatum passed over a double team, giving Boston a four-on-three, where Brown drove baseline and found a cutting Horford, who provided the exclamation mark on the Celtics' 120-108 win in Game 1 of the NBA Finals.

Tatum played nearly the entire fourth quarter but didn't score, making the come-from-behind victory even more impressive. And despite his shot not falling, it didn't negatively affect him defensively, and he impacted the outcome with his facilitating.

Tatum finished with a game-high 13 assists. Nine of them were on Boston's 21 makes from beyond the arc, setting the record for the most by any player in a Finals game. It exemplified the Celtics' resiliency and their ability to figure out what's needed for them to walk out with a win.

Further Reading

It's Taken Al Horford 15 Years to Reach the NBA Finals; He's Wasting No Time Maximizing His Opportunity

Celtics, Jayson Tatum Discuss His Growth as a Facilitator After He Sets NBA Finals Record

Celtics' Resiliency on Display in Fourth Quarter of Game 1 of NBA Finals: 'We're battle-tested; we've been through a lot'

What Stood Out in Game 1 of the NBA Finals: Celtics' Take Series Opener with Fourth-Quarter Haymaker

Tony Parker Sizes Up the NBA Finals, Talks Ime Udoka and His Collaboration with MTN Dew LEGEND

As the Calls to Separate Them Grew Louder, Jayson Tatum and Jaylen Brown Grew Closer: 'two young, extremely competitive guys that just really want to win at all costs'

View original post here:
The Anatomy of the Celtics' Fourth-Quarter Comeback in Game 1 of NBA Finals - Sports Illustrated

‘Anatomy of a Scandal’: Why There Won’t Be a Season 2 – PopCulture.com

Netflix found a huge hit in its anthology thriller series Anatomy of a Scandal, so fans are understandably confused that the series is not getting picked up. However, the show was "canceled" instead, it was always planned as a limited series. The six episodes of Anatomy of a Scandal were all that were ever planned by its creators.

Anatomy of a Scandal is a Netflix original series that premiered on April 15, 2022. It is a drama with elements of true crime, politics and mystery all mixed together in the story of a British family torn apart by a highly publicized scandal. The show is based on a novel of the same name written by Sarah Vaughan, and Vaughan never wrote a sequel. With the story relayed in its entirety already, there's no reason for a second season to be made.

Vaughan wrote Anatomy of a Scandal and published it in 2018, drawing on her own experience as a political journalist and a student at Oxford. It was her third novel, separate from the first two books and the two that have followed it since. Vaughan has not hinted at any plans to make a sequel, and fans of the genre aren't necessarily clamoring for one, either. The story is self-contained, and thrillers of this kind do not typically get serialized in the world of publishing.

TV is a different story. Many acclaimed thriller adaptations have been extended past their source material, with TV writers teasing out the story and following the characters onto their next adventure. However, this is not always popular, with fans sometimes complaining that it's easy to tell when the original story runs out and the show is running on fumes. One of the most infamous recent examples was at Netflix 13 Reasons Why.

It would make sense that Netflix wants to avoid this pitfall when it comes to Anatomy of a Scandal, ending the show on a high note. It's also notable that the book and the show are both British. Short limited series are much more common in the U.K., and book adaptations are rarely extended there. Viewers would like be surprised if Anatomy of a Scandal broke that norm.

Fans who are disappointed to leave the Whitehouse family behind can always turn to Vaughan's book. It is available now in print, digital and audiobook format wherever books are sold. Otherwise, the series is streaming now on Netflix.

See original here:
'Anatomy of a Scandal': Why There Won't Be a Season 2 - PopCulture.com

Biologist Shares Freakily Detailed Anatomical Illustrations of Pokmon – We Got This Covered

via The Pokemon Company

Do you ever wonder what a Pokmon would look like inside that cuddly exterior? No? Well, you can anyway after fan-made anatomically-accurate illustrations made their way online.

The images appeared on the Pokmon subreddit, where drawings of Cyndaquil, Octillery, Donphan, and Bellossom offered a detailed interpretation of the creatures anatomy. The drawings are very detailed, almost unsettlingly so, similar to what youd see in the doctors office. They even have names of the organs and details of bone structure for added accuracy.

Many commented underneath the thread on how horrifying (in a good way) these drawings are. Some also said that theyre now looking forward to their future nightmares.

Others, especially those either currently or aspiring to work in the field of biology, have praised the artist for the amount of detail these drawings have.

Fans showed excitement to see more, giving out requests for other Pokmon theyd like to see anatomically deconstructed. Some showed curiosity on how other Pokmon like ghost types or Cuebone would appear, considering that they have no bones usually, with the latter wearing skulls on their heads.

The original artist posted a link underneath the thread to their Poknatomy book, where they drew full-page anatomical illustrations of all the original 151 Pokmon. And while these drawings may look horrifying, you have to admit that the artist has placed a lot of effort to make them as detailed and convincing as possible.

'+// ''+// '

See the original post:
Biologist Shares Freakily Detailed Anatomical Illustrations of Pokmon - We Got This Covered

Michelle Dockery (Anatomy of a Scandal) on playing a prosecutor: I could get all of that rage and emotion out [Exclusive Video Interview] – Gold Derby

Shes really living a lie in many ways, declares Michelle Dockery about her character in the Netflix limited series Anatomy of a Scandal. The series developed and written by Melissa James Gibson and Emmy-winning writer and producer David E. Kelley, follows a wife and mother (Sienna Miller) who struggles to support her husband (Rupert Friend), a British politician who has had an affair and is accused of rape. Dockery plays Kate Woodcroft, the prosecuting attorney who endures her own lingering trauma. Check out our exclusive video chat with the four-time Emmy nominee above. Spoilers for the full season ahead.

The character of Kate turns out to be more than a mere attorney. The audience eventually learns that Kates real name is Holly Berry, and that as a student, Kate/Holly was raped by the same politician Kate is presently prosecuting. Dockery says that the characters duality was one of the key attractions of the role. Shes changed her identity to bury her past, she says. I loved that there is this fantastic kind of journey throughout the story for her because she starts out as this quite closed off human being and very guarded, and then as the story goes on those layers begin to peel back.

SEE over 350 interviews with 2022 Emmy contenders

Because the show was filmed out of sequence, Dockery shot her emotional breakdown for the final episode very early in the filming and spent a great deal of time isolated from the rest of the cast. The actress argues that the circumstances helped in portraying her character. It worked out great because I could get all of that rage and emotion out in those final moments with Kate and then sort of work backwards, she explains. That separation from everybody was really good because Kates a lone wolf. Shes very private and she likes to be alone. So it was good to get into the character in that sense.

Dockery says that the entire production went to extraordinary lengths to tackle the issue of sexual violence in a way that is both honest and respectful to victims, including working with victims advocate groups throughout the United Kingdom. Its obviously a subject that is a really sensitive one, and we were all adamant that it was delivered in the most authentic way possible, she says. The actress describes how it was sometimes difficult to leave the character behind after filming certain scenes. Whenever I do something that is sort of guttural and emotional, I go home and Ill feel tired and its a little harder to shake off, she claims.

PREDICT the 2022 Emmy nominees by July 12

Make your predictionsat Gold Derby now. Download our free and easy app forApple/iPhone devicesorAndroid (Google Play)to compete against legions of other fans plus our experts and editors for best prediction accuracy scores. See ourlatest prediction champs. Can you top our esteemed leaderboards next? Always remember to keep your predictions updated because they impact our latest racetrack odds, which terrify Hollywood chiefs and stars. Dont miss the fun. Speak up and share your huffy opinions in ourfamous forumswhere 5,000 showbiz leaders lurk every day to track latest awards buzz. Everybody wants to know: What do you think? Who do you predict and why?

SIGN UPfor Gold Derbys free newsletter with latest predictions

See more here:
Michelle Dockery (Anatomy of a Scandal) on playing a prosecutor: I could get all of that rage and emotion out [Exclusive Video Interview] - Gold Derby